{"id":"0cd83b28-d0e9-4f17-be61-c9d20d2b618f","name":"Motif Neurotech","slug":"motif-neurotech","description":"Motif Neurotech is a Houston-based brain-computer interface company developing an implantable therapeutic BCI for treatment-resistant depression. Its [Motif BCI](/models/motif-bci) XCS System is a wirelessly-powered implant delivering electrical stimulation to brain circuits linked to depression. FDA approved its first clinical trial (RESONATE) in April 2026, making Motif the fastest implantable BCI company from founding to IDE approval.","status":null,"founded":2022,"hq":"Houston, Texas, USA","hqLat":null,"hqLng":null,"hqGeocodedAt":null,"hqAddress":null,"hqPrecision":null,"website":"motifneuro.tech","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://news.rice.edu/news/2026/brain-computer-interface-based-rice-research-wins-fda-approval-first-clinical-trial","title":"Brain-computer interface based on Rice research wins FDA approval for first clinical trial","sourceName":"Rice University News"}],"keyFacts":[{"label":"FDA","value":"IDE approved April 2026"},{"label":"Indication","value":"Treatment-resistant depression"},{"label":"Program","value":"ARPA-H behavioral health"},{"label":"Origin","value":"Rice University research"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:32:35.528Z","updatedAt":"2026-08-08T22:39:11.506Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/motif-neurotech","url":"https://registry.deploy.report/companies/motif-neurotech","name":"Motif Neurotech","description":"Motif Neurotech is a Houston-based brain-computer interface company developing an implantable therapeutic BCI for treatment-resistant depression. Its [Motif BCI](/models/motif-bci) XCS System is a wirelessly-powered implant delivering electrical stimulation to brain circuits linked to depression. FDA approved its first clinical trial (RESONATE) in April 2026, making Motif the fastest implantable BCI company from founding to IDE approval.","identifier":"0cd83b28-d0e9-4f17-be61-c9d20d2b618f","foundingDate":"2022","address":"Houston, Texas, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}